Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Weight Loss | 24 | 2024 | 457 | 6.890 |
Why?
|
| Obesity | 28 | 2024 | 1152 | 5.200 |
Why?
|
| Caloric Restriction | 11 | 2024 | 101 | 3.710 |
Why?
|
| Body Composition | 15 | 2019 | 388 | 3.060 |
Why?
|
| Exercise | 12 | 2023 | 679 | 2.580 |
Why?
|
| Bone Density | 9 | 2024 | 203 | 2.450 |
Why?
|
| Diet, Reducing | 8 | 2020 | 100 | 2.410 |
Why?
|
| Inflammation | 10 | 2013 | 536 | 2.230 |
Why?
|
| Overweight | 8 | 2016 | 263 | 1.830 |
Why?
|
| Dietary Proteins | 4 | 2019 | 55 | 1.680 |
Why?
|
| Bone Density Conservation Agents | 2 | 2024 | 23 | 1.580 |
Why?
|
| Aged | 41 | 2024 | 10544 | 1.520 |
Why?
|
| Resistance Training | 3 | 2024 | 77 | 1.450 |
Why?
|
| Physical Fitness | 4 | 2013 | 133 | 1.390 |
Why?
|
| Aging | 9 | 2017 | 938 | 1.350 |
Why?
|
| Adipose Tissue | 4 | 2020 | 349 | 1.250 |
Why?
|
| Female | 49 | 2024 | 20271 | 1.230 |
Why?
|
| Bone and Bones | 3 | 2023 | 94 | 1.160 |
Why?
|
| Adiposity | 4 | 2020 | 198 | 1.120 |
Why?
|
| Interleukin-6 | 6 | 2023 | 240 | 1.080 |
Why?
|
| Humans | 56 | 2024 | 32814 | 1.080 |
Why?
|
| Male | 39 | 2024 | 19650 | 1.070 |
Why?
|
| Body Mass Index | 12 | 2023 | 908 | 1.050 |
Why?
|
| Weight Gain | 4 | 2017 | 112 | 1.010 |
Why?
|
| Gait | 2 | 2020 | 140 | 0.980 |
Why?
|
| Postmenopause | 7 | 2017 | 427 | 0.970 |
Why?
|
| Soy Milk | 3 | 2010 | 3 | 0.970 |
Why?
|
| Fractures, Bone | 4 | 2020 | 162 | 0.900 |
Why?
|
| Cardiovascular Diseases | 6 | 2019 | 1140 | 0.880 |
Why?
|
| Alendronate | 1 | 2024 | 11 | 0.880 |
Why?
|
| Soybean Proteins | 4 | 2015 | 77 | 0.880 |
Why?
|
| Middle Aged | 28 | 2024 | 12133 | 0.860 |
Why?
|
| Motor Activity | 4 | 2014 | 327 | 0.850 |
Why?
|
| Obesity, Morbid | 3 | 2020 | 69 | 0.840 |
Why?
|
| Gastrectomy | 2 | 2021 | 70 | 0.820 |
Why?
|
| Absorptiometry, Photon | 6 | 2024 | 136 | 0.780 |
Why?
|
| Muscle, Skeletal | 6 | 2023 | 524 | 0.740 |
Why?
|
| Milk | 3 | 2010 | 16 | 0.730 |
Why?
|
| Inflammation Mediators | 3 | 2012 | 102 | 0.690 |
Why?
|
| Uric Acid | 2 | 2013 | 27 | 0.680 |
Why?
|
| Mortality | 2 | 2019 | 124 | 0.680 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 25 | 0.650 |
Why?
|
| Continental Population Groups | 1 | 2020 | 236 | 0.590 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2016 | 1462 | 0.580 |
Why?
|
| Oxidative Stress | 2 | 2010 | 239 | 0.560 |
Why?
|
| Abdominal Fat | 2 | 2015 | 47 | 0.530 |
Why?
|
| Walking | 5 | 2020 | 210 | 0.520 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 48 | 0.500 |
Why?
|
| Cognition | 2 | 2016 | 551 | 0.460 |
Why?
|
| Life Style | 3 | 2014 | 407 | 0.450 |
Why?
|
| Muscle Strength | 2 | 2018 | 157 | 0.450 |
Why?
|
| Isoflavones | 3 | 2010 | 79 | 0.450 |
Why?
|
| Blood Pressure | 3 | 2015 | 862 | 0.430 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 543 | 0.420 |
Why?
|
| Cytokines | 3 | 2011 | 247 | 0.420 |
Why?
|
| Adiponectin | 2 | 2013 | 103 | 0.420 |
Why?
|
| Diet | 3 | 2011 | 390 | 0.410 |
Why?
|
| Prediabetic State | 1 | 2014 | 72 | 0.410 |
Why?
|
| Pilot Projects | 4 | 2021 | 565 | 0.390 |
Why?
|
| Soy Foods | 2 | 2010 | 7 | 0.390 |
Why?
|
| Cause of Death | 1 | 2013 | 240 | 0.380 |
Why?
|
| Single-Blind Method | 6 | 2015 | 195 | 0.380 |
Why?
|
| Follow-Up Studies | 8 | 2017 | 2285 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 532 | 0.380 |
Why?
|
| Nonprescription Drugs | 2 | 2009 | 23 | 0.380 |
Why?
|
| Insulin Resistance | 2 | 2014 | 469 | 0.370 |
Why?
|
| Coronary Disease | 1 | 2013 | 214 | 0.370 |
Why?
|
| Age Factors | 5 | 2020 | 1197 | 0.360 |
Why?
|
| Corn Oil | 2 | 2009 | 3 | 0.360 |
Why?
|
| Risk Factors | 8 | 2017 | 3976 | 0.350 |
Why?
|
| Tumor Necrosis Factors | 1 | 2010 | 5 | 0.340 |
Why?
|
| Dietary Supplements | 3 | 2012 | 187 | 0.340 |
Why?
|
| North Carolina | 4 | 2019 | 1546 | 0.340 |
Why?
|
| Interleukins | 1 | 2010 | 18 | 0.340 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2010 | 46 | 0.330 |
Why?
|
| Sarcopenia | 3 | 2017 | 66 | 0.330 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 754 | 0.330 |
Why?
|
| Exercise Therapy | 1 | 2013 | 271 | 0.320 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 125 | 0.320 |
Why?
|
| Enzymes | 1 | 2009 | 5 | 0.310 |
Why?
|
| Fish Oils | 1 | 2009 | 35 | 0.310 |
Why?
|
| Plant Preparations | 1 | 2009 | 27 | 0.310 |
Why?
|
| Soybeans | 1 | 2009 | 35 | 0.310 |
Why?
|
| Lipoprotein(a) | 1 | 2009 | 22 | 0.300 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 36 | 0.300 |
Why?
|
| Lipids | 1 | 2010 | 229 | 0.300 |
Why?
|
| Renal Dialysis | 2 | 2009 | 280 | 0.300 |
Why?
|
| Double-Blind Method | 3 | 2021 | 525 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2018 | 949 | 0.290 |
Why?
|
| Muscular Atrophy | 1 | 2009 | 76 | 0.290 |
Why?
|
| Hyperhomocysteinemia | 1 | 2008 | 5 | 0.280 |
Why?
|
| Time Factors | 4 | 2017 | 2183 | 0.280 |
Why?
|
| Homocysteine | 1 | 2008 | 15 | 0.280 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2008 | 29 | 0.280 |
Why?
|
| Docosahexaenoic Acids | 1 | 2008 | 20 | 0.280 |
Why?
|
| Lumbar Vertebrae | 3 | 2019 | 110 | 0.280 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 4034 | 0.280 |
Why?
|
| Osteoporosis | 3 | 2024 | 71 | 0.260 |
Why?
|
| Energy Intake | 2 | 2019 | 128 | 0.260 |
Why?
|
| Health Status | 3 | 2016 | 402 | 0.250 |
Why?
|
| Prospective Studies | 5 | 2015 | 2329 | 0.250 |
Why?
|
| Treatment Outcome | 6 | 2020 | 3441 | 0.240 |
Why?
|
| Survival Analysis | 2 | 2017 | 486 | 0.210 |
Why?
|
| Research Design | 1 | 2024 | 332 | 0.190 |
Why?
|
| Prevalence | 3 | 2017 | 1002 | 0.180 |
Why?
|
| Prognosis | 2 | 2017 | 1545 | 0.180 |
Why?
|
| Carbohydrate Metabolism | 1 | 2020 | 17 | 0.170 |
Why?
|
| Self-Help Devices | 1 | 2020 | 8 | 0.170 |
Why?
|
| Accidents, Home | 1 | 2020 | 17 | 0.170 |
Why?
|
| Environment Design | 1 | 2020 | 18 | 0.170 |
Why?
|
| Femur Neck | 2 | 2017 | 21 | 0.160 |
Why?
|
| Amino Acids | 1 | 2020 | 46 | 0.160 |
Why?
|
| Metabolomics | 1 | 2020 | 55 | 0.160 |
Why?
|
| Glutathione Peroxidase | 2 | 2010 | 10 | 0.160 |
Why?
|
| Housing | 1 | 2020 | 65 | 0.160 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 42 | 0.160 |
Why?
|
| Disability Evaluation | 3 | 2020 | 238 | 0.160 |
Why?
|
| Cyclooxygenase 2 | 2 | 2010 | 50 | 0.160 |
Why?
|
| Animals | 5 | 2017 | 7570 | 0.160 |
Why?
|
| United States | 3 | 2016 | 4109 | 0.150 |
Why?
|
| Exercise Test | 2 | 2019 | 223 | 0.150 |
Why?
|
| Hip | 1 | 2019 | 15 | 0.150 |
Why?
|
| Femur | 1 | 2019 | 79 | 0.140 |
Why?
|
| Compressive Strength | 1 | 2018 | 22 | 0.140 |
Why?
|
| Clothing | 1 | 2018 | 6 | 0.140 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 23 | 0.130 |
Why?
|
| Oxygen Consumption | 3 | 2019 | 150 | 0.130 |
Why?
|
| Hand Strength | 2 | 2015 | 101 | 0.130 |
Why?
|
| Muscle Denervation | 1 | 2017 | 27 | 0.130 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2017 | 28 | 0.130 |
Why?
|
| Risk Assessment | 4 | 2017 | 1461 | 0.130 |
Why?
|
| Hip Fractures | 1 | 2017 | 30 | 0.130 |
Why?
|
| Behavior Therapy | 2 | 2016 | 103 | 0.130 |
Why?
|
| Thigh | 1 | 2016 | 40 | 0.120 |
Why?
|
| Troponin T | 1 | 2017 | 92 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2014 | 459 | 0.120 |
Why?
|
| Women | 1 | 2015 | 12 | 0.120 |
Why?
|
| Geriatric Assessment | 2 | 2020 | 388 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2020 | 828 | 0.110 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 363 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2016 | 1844 | 0.110 |
Why?
|
| Wrist Injuries | 1 | 2015 | 47 | 0.110 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 40 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3705 | 0.110 |
Why?
|
| Risk | 1 | 2015 | 315 | 0.100 |
Why?
|
| Interleukin-1beta | 2 | 2012 | 40 | 0.100 |
Why?
|
| Heart Function Tests | 1 | 2013 | 8 | 0.100 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2013 | 17 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 282 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 13 | 0.100 |
Why?
|
| Movement Disorders | 1 | 2013 | 26 | 0.100 |
Why?
|
| Interleukin-8 | 1 | 2013 | 24 | 0.100 |
Why?
|
| Muscle Development | 1 | 2013 | 49 | 0.100 |
Why?
|
| Community Health Centers | 1 | 2013 | 16 | 0.100 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 237 | 0.100 |
Why?
|
| Body Weight | 1 | 2015 | 301 | 0.100 |
Why?
|
| Leptin | 1 | 2013 | 73 | 0.100 |
Why?
|
| Triglycerides | 2 | 2012 | 228 | 0.100 |
Why?
|
| Body Weights and Measures | 1 | 2013 | 23 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 563 | 0.100 |
Why?
|
| Disease Progression | 1 | 2014 | 594 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 779 | 0.090 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 77 | 0.090 |
Why?
|
| Dairy Products | 1 | 2012 | 13 | 0.090 |
Why?
|
| Independent Living | 1 | 2013 | 105 | 0.090 |
Why?
|
| Health Education | 1 | 2013 | 162 | 0.090 |
Why?
|
| Body Fluid Compartments | 1 | 2011 | 4 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 676 | 0.090 |
Why?
|
| Food, Formulated | 1 | 2011 | 12 | 0.090 |
Why?
|
| Health Behavior | 1 | 2013 | 234 | 0.090 |
Why?
|
| Mobility Limitation | 1 | 2013 | 220 | 0.090 |
Why?
|
| Fibrinogen | 1 | 2011 | 45 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2011 | 48 | 0.080 |
Why?
|
| Adult | 4 | 2014 | 9569 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 59 | 0.080 |
Why?
|
| Cattle | 1 | 2010 | 108 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2010 | 85 | 0.080 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 80 | 0.080 |
Why?
|
| Vasodilation | 1 | 2010 | 92 | 0.080 |
Why?
|
| Models, Biological | 1 | 2012 | 392 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2010 | 155 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 213 | 0.080 |
Why?
|
| Health Promotion | 1 | 2011 | 255 | 0.070 |
Why?
|
| Health Surveys | 1 | 2009 | 200 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 410 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 163 | 0.070 |
Why?
|
| Texas | 1 | 2008 | 40 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2009 | 272 | 0.070 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 252 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 467 | 0.070 |
Why?
|
| Nutrition Surveys | 1 | 2009 | 150 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2008 | 191 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1572 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 576 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2018 | 181 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2019 | 494 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 1239 | 0.040 |
Why?
|
| Energy Metabolism | 2 | 2014 | 155 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 258 | 0.040 |
Why?
|
| Fatigue | 1 | 2019 | 83 | 0.040 |
Why?
|
| Women's Health | 1 | 2020 | 235 | 0.040 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 120 | 0.030 |
Why?
|
| Finite Element Analysis | 1 | 2018 | 83 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2017 | 8 | 0.030 |
Why?
|
| Causality | 1 | 2017 | 39 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 90 | 0.030 |
Why?
|
| California | 1 | 2017 | 66 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 308 | 0.030 |
Why?
|
| Neuromuscular Junction | 1 | 2017 | 66 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2017 | 113 | 0.030 |
Why?
|
| Organ Size | 1 | 2017 | 219 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 186 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2017 | 115 | 0.030 |
Why?
|
| Spine | 1 | 2015 | 44 | 0.030 |
Why?
|
| Publication Bias | 1 | 2015 | 8 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 573 | 0.030 |
Why?
|
| Calibration | 1 | 2015 | 28 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 764 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 767 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 475 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 201 | 0.030 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 195 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 888 | 0.020 |
Why?
|
| Accidents, Traffic | 1 | 2015 | 197 | 0.020 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2012 | 3 | 0.020 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2012 | 9 | 0.020 |
Why?
|
| Running | 1 | 2012 | 19 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 175 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2012 | 18 | 0.020 |
Why?
|
| Calpain | 1 | 2012 | 13 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 76 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2012 | 171 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2012 | 63 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 199 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2011 | 9 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2512 | 0.020 |
Why?
|
| Insulin | 1 | 2012 | 367 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 105 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 498 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 218 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 682 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 343 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 215 | 0.020 |
Why?
|